在非小细胞肺癌中的KIAA1429:将m6A表观遗传与治疗创新的桥梁
Hui Liu1, Ke Shi2, Liang Liu3,4
1Department of Ultrasound Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Frontiers in surgery
|November 5, 2025
概括
KIAA1429通过表观遗传机制驱动非小细胞肺癌 (NSCLC) 的进展和耐药性. 准KIAA1429为NSCLC患者的精密治疗提供了一个有前途的战略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- KIAA1429是m6A甲基转移酶复合物的关键组成部分.
- 它的过度表达与侵袭性非小细胞肺癌 (NSCLC) 和预后不佳有关.
- KIAA1429 影响瘤发生,转移和治疗耐药性.
研究的目的:
- 审查KIAA1429在NSCLC发病过程中的作用.
- 阐明KIAA1429对下游目标的m6A依赖调节.
- 突出KIAA1429作为NSCLC的潜在治疗点.
主要方法:
- 在NSCLC中对KIAA1429进行全面的文献综述.
- 分析KIAA1429表达模式和临床相关性.
- 检查KIAA1429的分子机制和下游效应器.
主要成果:
- 过度表达KIAA1429与晚期NSCLC和不良结果相关.
- KIAA1429通过m6A调节了HOXA1,DAPK3和BTG2等关键效应器.
- 失调的KIAA1429驱动NSCLC的恶性转变.
结论:
- KIAA1429是NSCLC的一个关键表观遗传调节剂.
- 准KIAA1429为NSCLC精密瘤学提供了一个新的途径.
- 对KIAA1429抑制剂的进一步研究是有必要的.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.6K
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.8K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
